RegulatoryMay 26, 2026, 08:32 AM
Microbot Medical LIBERTY System Gets Israel Marketing Clearance
AI Summary
Microbot Medical Inc. announced that Israel has granted marketing clearance for its LIBERTY Endovascular Robotic System, making it the second jurisdiction and the first outside the U.S. to do so. This regulatory approval from the Israeli Ministry of Health's AMAR Division allows the company to market and commercialize the system in Israel and obtain a Free Sale Certificate to support expansion into other international markets. The company is also working towards CE Mark certification by the end of 2026 for entry into the EU market, following a successful launch in the U.S. where it has been adopted by multiple hospitals.
Key Highlights
- Israel grants marketing clearance for Microbot Medical's LIBERTY System.
- Israel is the second jurisdiction and first outside the U.S. to approve the LIBERTY System.
- The approval enables obtaining a Free Sale Certificate for additional jurisdictions.
- Company is pursuing CE Mark certification for EU market by end of 2026.
- LIBERTY System successfully launched and adopted in multiple U.S. states.
Price Impact
More from MBOT